Caladrius Biosciences Inc (CLBS) Stock
CLBS is no longer traded. Caladrius Biosciences was delisted from the Nasdaq in September 2022.
Prices on this page are historical; the last trade was September 14, 2022 at $0.43.
Caladrius Biosciences stock price history
CLBS final trading statistics
- Final close
- $0.43
- Final trading day
- Sep 14, 2022
- Market cap at delisting
- $25.83M
- Shares outstanding
- 60.58M
- Final 52-week range
- $0.03 – $0.65
- Avg. volume (final 3 mo.)
- 580,653
- All-time high (split-adj.)
- $23.36 · Jun 2015
- All-time low (split-adj.)
- $0.41 · May 2022
- Return since IPO
- -98.2%
- Beta
- 0.91
- Book value / share
- $1.36
- Price / book
- 0.31
Caladrius Biosciences annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2021 | $0.00 | -$27.5M | -$7.80 |
| FY2020 | $0.00 | -$8.2M | -$8.43 |
| FY2019 | $0.00 | -$19.4M | -$1.87 |
| FY2018 | $0.00 | -$16.2M | -$1.66 |
| FY2017 | $0.00 | $23.0M | -$2.13 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Caladrius Biosciences Inc
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Caladrius Biosciences stock FAQ
What happened to Caladrius Biosciences stock?
Caladrius Biosciences stock was delisted from the Nasdaq. Its final close was $0.43 on September 14, 2022.
Is CLBS stock still trading?
No. CLBS was delisted from the Nasdaq in September 2022 and no longer trades on a U.S. exchange.
What was the last price of CLBS stock?
CLBS closed at $0.43 on its final trading day, September 14, 2022, for a market value of about $25.83M.
What were Caladrius Biosciences's revenue and earnings in its last full fiscal year?
Caladrius Biosciences reported revenue of $0.00 and net income of -$27.5M in fiscal 2021, its last full year as a public company.
When did Caladrius Biosciences go public?
Caladrius Biosciences Inc stock began trading on March 1, 1999.